All Stories

  1. Human oligodendrocyte progenitor cells mediate synapse elimination through TAM receptor activation
  2. Long‐Term Use of Benzodiazepines and Related Drugs in Persons With Major Depressive Disorder
  3. Relapse risk prediction in patients with first-episode bipolar disorder: development, external validation, and pharmacotherapy associations of a machine learning model
  4. Psychopathic Traits Associate With Later Schizophrenia
  5. Brexpiprazole in the Management of Schizophrenia: A Consensus Report of Best Practices From Acute to Maintenance Treatment
  6. Long term safety of ADHD medication in patients with schizophrenia spectrum disorders
  7. Metabolic Alterations in Human Post‐Mortem Frontal Cortex and Cerebrospinal Fluid Associated With High Levels of Nicotine Metabolite Cotinine
  8. Continuous Dopamine D2 Receptor Blockade and Long-Term Outcome in First-Episode Schizophrenia
  9. Is it Possible To Identify Patients After Their First Hospitalization for a Psychotic Disorder Who Do Not Use Anti-Psychotics and are Not Later Rehospitalized?
  10. miRNA profiling of hiPSC-derived neurons from monozygotic twins discordant for schizophrenia
  11. Sex-stratified mortality estimates in people with schizophrenia: A systematic review and meta-analysis of cohort studies of 2,700,825 people with schizophrenia
  12. Metabolic alterations in human post-mortem frontal cortex and cerebrospinal fluid associated with high levels of nicotine metabolite cotinine
  13. The challenges of antipsychotic polypharmacy
  14. Antipsychotic Monotherapy vs Polytherapy for Pneumonia Risk—Reply
  15. Labor market marginalization in individuals with bipolar disorder: a Swedish nationwide register-based sibling comparison study
  16. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder
  17. Effects of antipsychotic treatment on cardio-cerebrovascular related mortality in schizophrenia: A subanalysis of a systematic review and meta-analysis with meta-regression of moderators
  18. Dosing levels of antipsychotics and mood stabilizers in bipolar disorder: A Nationwide cohort study on relapse risk and treatment safety
  19. Severe side effects of the most effective schizophrenia medication
  20. Pneumonia Risk, Antipsychotic Dosing, and Anticholinergic Burden in Schizophrenia
  21. Association of obesity to reaction time and visual memory in schizophrenia
  22. Characteristics of high-dose benzodiazepine use: nationwide cohort study on new benzodiazepine users with 5-year follow-up
  23. Aberrant type 2 dopamine receptor availability in violent offenders with psychopathy
  24. Astrocytes Regulate Neuronal Network Burst Frequency Through NMDA Receptors in a Species- and Donor-Specific Manner
  25. Cardiovascular mortality in bipolar disorder: Population‐based cohort study
  26. Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case–control study in Finland
  27. Real‐world effectiveness of antidepressants, antipsychotics and their combinations in the maintenance treatment of psychotic depression. Evidence from within‐subject analyses of two nationwide cohorts
  28. Medication use and sickness absence from work in bipolar disorder: a nationwide register‐based study
  29. Antipsychotic Use and Risk of Breast Cancer in Women With Severe Mental Illness: Replication of a Nationwide Nested Case–Control Database Study
  30. Integrative metabolomics-genomics analysis identifies key networks in a stem cell-based model of schizophrenia
  31. Antipsychotic Use and Psychiatric Hospitalization in First-Episode Non-affective Psychosis and Cannabis Use Disorder: A Swedish Nationwide Cohort Study
  32. Development and Validation of a Machine Learning–Based Model of Mortality Risk in First-Episode Psychosis
  33. Navigated and individual α-peak-frequency–guided transcranial magnetic stimulation in male patients with treatment-refractory schizophrenia
  34. Regional differences in mortality risk and in attenuating or aggravating factors in schizophrenia: A systematic review and meta-analysis
  35. Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data
  36. Relative Risk of Breast Cancer Associated With Prolactin-Increasing Antipsychotic Use
  37. Long-term benzodiazepine use and risk of labor market marginalization in Finland: A cohort study with 5-year follow-up
  38. Effect of severity of depression on augmentation of antidepressant medication in young adults with depression
  39. Non-adherence to mood stabilizers and antipsychotics among persons with bipolar disorder – A nationwide cohort study
  40. β2-Adrenoceptor Agonists in Asthma or Chronic Obstructive Pulmonary Disease and Risk of Parkinson’s Disease: Nested Case-Control Study
  41. Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects
  42. Safety of Antipsychotic Polypharmacy Versus Monotherapy in a Nationwide Cohort of 61,889 Patients With Schizophrenia
  43. Association of pharmacological treatments and real‐world outcomes in borderline personality disorder
  44. Cohort profile: SUPER-Finland – the Finnish study for hereditary mechanisms of psychotic disorders
  45. Functional Characterization of Six SLCO1B1 (OATP1B1) Variants Observed in Finnish Individuals with a Psychotic Disorder
  46. Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study
  47. Associations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia
  48. Association of Pharmacological Treatments and Hospitalization and Death in Individuals With Amphetamine Use Disorders in a Swedish Nationwide Cohort of 13 965 Patients
  49. Psychotic depression and deaths due to suicide
  50. Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosis
  51. Validation of the collaborative outcomes study on health and functioning during infection times (COH-FIT) questionnaire for adults
  52. Factors and their weight in reducing life expectancy in schizophrenia
  53. Antipsychotic Use and Risk of Low-Energy Fractures in People With Schizophrenia: A Nationwide Nested Case-Control Study in Finland
  54. Mortality in psychotic depression: 18-year follow-up study
  55. Twenty‐year medication use trends in first‐episode bipolar disorder
  56. Women with Schizophrenia-Spectrum Disorders After Menopause: A Vulnerable Group for Relapse
  57. Mu-opioid receptor system modulates responses to vocal bonding and distress signals in humans
  58. Real‐world effectiveness of mood stabilizer use in schizophrenia
  59. Allopurinol, dipyridamole and calcium channel blockers in the treatment of bipolar disorder – A nationwide cohort study
  60. Associations between antipsychotic use, substance use and relapse risk in patients with schizophrenia: real-world evidence from two national cohorts
  61. Comparative effectiveness of mood stabilizers and antipsychotics in the prevention of hospitalization after lithium discontinuation in bipolar disorder
  62. Healthcare utilization, costs, and productivity losses in treatment-resistant depression in Finland – a matched cohort study
  63. Clozapine and the risk of haematological malignancies – Authors' reply
  64. Courses of treatment and risk factors for treatment-resistant depression in Finnish primary and special healthcare: A nationwide cohort study
  65. Real-world effectiveness studies of low doses of antipsychotics – Authors' reply
  66. Differences in psychosocial functioning between psychotic disorders in the Finnish SUPER study
  67. Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia
  68. Mortality in people with schizophrenia: a systematic review and meta‐analysis of relative risk and aggravating or attenuating factors
  69. Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland
  70. Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends
  71. Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders
  72. Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study
  73. Aberrant motor contagion of emotions in psychopathy and high-functioning autism
  74. Female Psychopathy and Mortality
  75. Primary Nonadherence to Antipsychotic Treatment Among Persons with Schizophrenia
  76. Clinical and societal burden of incident major depressive disorder: A population‐wide cohort study in Stockholm
  77. Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials
  78. Implementation of CYP2D6 copy-number imputation panel and frequency of key pharmacogenetic variants in Finnish individuals with a psychotic disorder
  79. Real‐world effectiveness of pharmacological treatments of opioid use disorder in a national cohort
  80. The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic
  81. Brain structural alterations in autism and criminal psychopathy
  82. The iPSC perspective on schizophrenia
  83. Contribution of astrocytes to familial risk and clinical manifestation of schizophrenia
  84. Switches and early discontinuations of antidepressant medication in young adults with depression
  85. Exploring the relation between high-activity COMT Val158Met genotype and psychopathy in male offenders
  86. Correspondence regarding De Girolamo et al., 2021 ‘A multinational case–control study comparing forensic and non-forensic patients with schizophrenia spectrum disorders: the EU-VIORMED project’
  87. Reaction Time and Visual Memory in Connection to Hazardous Drinking Polygenic Scores in Schizophrenia, Schizoaffective Disorder and Bipolar Disorder
  88. Clozapine, Long-Acting Injectables (and Polypharmacy?) Superior in U.S. and International Registries
  89. Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland
  90. Reaction Time and Visual Memory in Connection to Alcohol Use in Persons with Bipolar Disorder
  91. Associations of age, sex, sexual abuse, and genotype with monoamine oxidase a gene methylation
  92. Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study
  93. Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
  94. Antipsychotic discontinuation: mind the patient and the real-world evidence
  95. Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study
  96. Continuity of antipsychotic medication use among migrant and Finnish-born populations with a psychotic disorder: a register-based study
  97. Molecular signaling pathways underlying schizophrenia
  98. Reaction Time and Visual Memory in Connection with Alcohol Use in Schizophrenia and Schizoaffective Disorder
  99. Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort
  100. HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and agranulocytosis in individuals of European ancestry
  101. Brain Basis of Psychopathy in Criminal Offenders and General Population
  102. Hip Fracture Risk in Antiepileptic Drug Initiators and Non-Initiators with Alzheimer’s Disease
  103. Registry-based studies: What they can tell us, and what they cannot
  104. Incidence of schizophrenia and influence of prenatal and infant exposure to viral infectious diseases
  105. Changes in the metabolic profile of human male postmortem frontal cortex and cerebrospinal fluid samples associated with heavy alcohol use
  106. Morbidity and mortality in schizophrenia with comorbid substance use disorders
  107. Voluntary patient safety incidents reporting in forensic psychiatry—What do the reports tell us?
  108. Long-Term Real-World Effectiveness of Pharmacotherapies for Schizoaffective Disorder
  109. Effectiveness of pharmacotherapies for delusional disorder in a Swedish national cohort of 9076 patients
  110. Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia
  111. Risk of labour market marginalisation among young refugees and non-refugee migrants with common mental disorders
  112. Real‐world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation‐wide cohort of 125 556 patients
  113. Long-Term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study
  114. Antipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences
  115. Rejoinder to rejoinder to commentary
  116. Suicide mortality and use of psychotropic drugs in patients hospitalized due to bipolar disorder: A Finnish nationwide cohort study
  117. Employment among people with schizophrenia or bipolar disorder: A population‐based study using nationwide registers
  118. Medication management of antipsychotic treatment in schizophrenia—A narrative review
  119. Causes of death in a nationwide cohort of community-dwellers with Alzheimer’s disease
  120. P.810Real-world effectiveness of mood stabilizer use in persons with schizophrenia
  121. Incidence of and Characteristics Associated With Long-term Benzodiazepine Use in Finland
  122. Commentary on Robert Whitaker's viewpoint
  123. Detection of medications associated with Alzheimer's disease using ensemble methods and cooperative game theory
  124. Corrigendum to “Monoamine oxidase A genotype and methylation moderate the association of maltreatment and aggressive behaviour” [Behav. Brain Res. 382 (2020) 112476]
  125. Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis
  126. Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia
  127. Length of Hospital Stay for Hip Fracture and 30-Day Mortality in People With Alzheimer’s Disease: A Cohort Study in Finland
  128. Medication Use and Health Care Utilization After a Cost-sharing Increase in Schizophrenia
  129. Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real‐World Study Across Antipsychotics
  130. Antiepileptic drug use and mortality among community-dwelling persons with Alzheimer disease
  131. Risk and risk factors for disability pension among patients with treatment resistant depression– a matched cohort study
  132. The clinical course of schizophrenia in women and men—a nation-wide cohort study
  133. T208. EFFECTIVENESS OF PHARMACOLOGICAL THERAPIES FOR DELUSIONAL DISORDER
  134. Monoamine oxidase A genotype and methylation moderate the association of maltreatment and aggressive behaviour
  135. A Systematic Literature Review of Neuroimaging of Psychopathic Traits
  136. Asthma and Chronic Obstructive Pulmonary Disease as a Comorbidity and Association with the Choice of Antidementia Medication Among Persons with Alzheimer’s Disease
  137. Prevalence of cardiovascular drug use before and after diagnosis of Alzheimer's disease
  138. Health and work disability outcomes in parents of patients with schizophrenia associated with antipsychotic exposure by the offspring
  139. Use of antidepressants and mood stabilizers in persons with first-episode schizophrenia
  140. 20‐year follow‐up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)
  141. In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine
  142. The Risk of Head Injuries Associated With Antipsychotic Use Among Persons With Alzheimer's disease
  143. Opioid Use After Hospital Care due to Hip Fracture Among Community-Dwelling Persons With and Without Alzheimer’s Disease
  144. Accumulation of Hospital Days Among Antipsychotic Initiators With Alzheimer's Disease
  145. Metformin and Risk of Alzheimer’s Disease Among Community-Dwelling People With Diabetes: A National Case-Control Study
  146. Correction: Neurobiological roots of psychopathy
  147. Substance Abuse and Excessive Mortality Among Forensic Psychiatric Patients: A Finnish Nationwide Cohort Study
  148. Sex-specific transcriptional and proteomic signatures in schizophrenia
  149. Neurobiological roots of psychopathy
  150. Predictors of high hospital care and medication costs and cost trajectories in community-dwellers with Alzheimer’s disease
  151. Cortical structure abnormalities in females with conduct disorder prior to age 15
  152. Adherence to psychotropic medication in completed suicide in Sweden 2006–2013: a forensic-toxicological matched case-control study
  153. Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study
  154. Hospital-Treated Pneumonia Associated with Opioid Use Among Community Dwellers with Alzheimer’s Disease
  155. Antiepileptic Drugs and Accumulation of Hospital Days Among Persons With Alzheimer's Disease
  156. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia
  157. Increased [³H]quisqualic acid binding density in the dorsal striatum and anterior insula of alcoholics: A post-mortem whole-hemisphere autoradiography study
  158. Long-term thiazide use and risk of low-energy fractures among persons with Alzheimer’s disease—nested case-control study
  159. Changes in patient safety culture: A patient safety intervention for Finnish forensic psychiatric hospital staff
  160. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review
  161. Trajectories of sickness absence, disability pension and unemployment in young immigrants with common mental disorders
  162. Antiepileptic Drug Use Is Associated with an Increased Risk of Pneumonia Among Community-Dwelling Persons with Alzheimer’s Disease-Matched Cohort Study
  163. Incidence of head injury and traumatic brain injury among people with Alzheimer’s disease
  164. Manifesto for an international digital mental health network
  165. Risk of Treatment Failure: Response to Ghosh and Noble
  166. Associations of Psychopathic Traits With Local and Global Brain Network Topology in Young Adult Women
  167. Response to the editorial on antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia
  168. Concomitant use of benzodiazepines and opioids in community‐dwelling older people with or without Alzheimer's disease—A nationwide register‐based study in Finland
  169. Duration of new antidepressant use and factors associated with discontinuation among community-dwelling persons with Alzheimer’s disease
  170. Comorbid opioid use is undertreated among forensic patients with schizophrenia
  171. Psychotropic drugs use and psychotropic polypharmacy among persons with Alzheimer's disease
  172. Incidence and prevalence of antiepileptic drugs use in persons with Alzheimer's disease.
  173. Systemic Estrogen Use and Discontinuation After Alzheimer’s Disease Diagnosis in Finland 2005–2012: A Nationwide Exposure-Matched Cohort Study
  174. Incident opioid use and risk of hip fracture among persons with Alzheimer disease: a nationwide matched cohort study
  175. Antipsychotic Use and the Risk of Initiating Medication for Benign Prostate Hyperplasia in Persons With Alzheimer Disease
  176. Antiepileptic Drug Use and the Risk of Stroke Among Community‐Dwelling People With Alzheimer Disease: A Matched Cohort Study
  177. Burden for Parents of Patients With Schizophrenia—A Nationwide Comparative Study of Parents of Offspring With Rheumatoid Arthritis, Multiple Sclerosis, Epilepsy, and Healthy Controls
  178. Risk of Treatment Failure: Response to Czobor and Volavka
  179. 20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia
  180. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia
  181. Hospitalization after Oral Antibiotic Initiation in Finnish Community Dwellers with and without Alzheimer’s Disease: Retrospective Register-Based Cohort Study
  182. Mortality in schizophrenia: 30‐year nationwide follow‐up study
  183. The risk of Alzheimer's disease associated with benzodiazepines and related drugs: a nested case–control study
  184. Editorial: let's take a break from studying the PPI‐fracture association—Authors’ reply
  185. Trends in the long‐term use of benzodiazepine anxiolytics and hypnotics: A national register study for 2006 to 2014
  186. Cause-specific mortality in Finnish forensic psychiatric patients
  187. Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder
  188. Associations of monoamine oxidase A gene first exon methylation with sexual abuse and current depression in women
  189. Comparison of dispensed medications and forensic‐toxicological findings to assess pharmacotherapy in the Swedish population 2006 to 2013
  190. Use of Antiepileptic Drugs and Dementia Risk—an Analysis of Finnish Health Register and German Health Insurance Data
  191. Impact of opioid initiation on antipsychotic and benzodiazepine and related drug use among persons with Alzheimer's disease
  192. Proton pump inhibitor use and risk of hip fractures among community‐dwelling persons with Alzheimer's disease—a nested case‐control study
  193. Initiation and long‐term use of benzodiazepines and Z‐drugs in bipolar disorder
  194. Platelet monoamine oxidase activity and interpersonal violence in male suicide attempters
  195. Associations Between MAOA‐uVNTR Genotype, Maltreatment, MAOA Methylation, and Alcohol Consumption in Young Adult Males
  196. Amygdala-orbitofrontal structural and functional connectivity in females with anxiety disorders, with and without a history of conduct disorder
  197. Firesetting and general criminal recidivism among a consecutive sample of Finnish pretrial male firesetters: A register-based follow-up study
  198. Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia—A Nationwide Study With 20-Year Follow-up
  199. Genome-Wide Association Studies of a Broad Spectrum of Antisocial Behavior
  200. No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer’s Disease
  201. Risk of disability pension in first and second generation immigrants: the role of age and region of birth in a prospective population-based study from Sweden
  202. Healthcare use among immigrants and natives in Sweden on disability pension, before and after changes of regulations
  203. Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: A matched cohort study
  204. Nurses’ Views Highlight a Need for the Systematic Development of Patient Safety Culture in Forensic Psychiatry Nursing
  205. De‐escalation techniques used, and reasons for seclusion and restraint, in a forensic psychiatric hospital
  206. Drug exposure in register-based research—An expert-opinion based evaluation of methods
  207. Trajectories and characteristics of work disability before and after acute myocardial infarction
  208. Use of lithium in patients with unipolar depression – Author's reply
  209. Is Alzheimer’s Disease Associated with Previous Opioid Use?
  210. Effects of Scheduled Waiting for Psychotherapy in Patients With Major Depression
  211. Reducing the rehospitalization risk after a manic episode: A population based cohort study of lithium, valproate, olanzapine, quetiapine and aripiprazole in monotherapy and combinations
  212. Risk of head and traumatic brain injuries associated with antidepressant use among community-dwelling persons with Alzheimer’s disease: a nationwide matched cohort study
  213. The Association of Ambient Temperature and Violent Crime
  214. White matter correlates of psychopathic traits in a female community sample
  215. Brain structure abnormalities in young women who presented conduct disorder in childhood/adolescence
  216. Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study
  217. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia
  218. Long-term use of proton pump inhibitors among community-dwelling persons with and without Alzheimer’s disease
  219. Hospital-treated mental and behavioral disorders and risk of Alzheimer's disease: A nationwide nested case-control study
  220. Psychopathy and Mortality
  221. Screening approach for identifying candidate drugs and drug‐drug interactions related to hip fracture risk in persons with Alzheimer disease
  222. Incident Use of a Potentially Inappropriate Medication and Hip Fracture in Community-Dwelling Older Persons With Alzheimer’s Disease
  223. Seasonal variation of hospital violence, seclusion and restraint in a forensic psychiatric hospital
  224. Use of benzodiazepines and related drugs is associated with a risk of stroke among persons with Alzheimer’s disease
  225. Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease
  226. Risk of Alzheimer’s disease among users of postmenopausal hormone therapy: A nationwide case-control study
  227. Antipsychotic Use and the Risk of Hip Fracture Among Community-Dwelling Persons With Alzheimer’s Disease
  228. Regional changes in psychotropic use among Finnish persons with newly diagnosed Alzheimer’s disease in 2005-2011
  229. Risk of Mortality Associated with Antipsychotic Monotherapy and Polypharmacy Among Community-Dwelling Persons with Alzheimer’s Disease
  230. Anticholinergic Exposure and Risk of Pneumonia in Persons with Alzheimer’s Disease: A Nested Case-Control Study
  231. Antidepressant use and risk of hip fractures among community‐dwelling persons with and without Alzheimer's disease
  232. Risk of Hip Fracture in Benzodiazepine Users With and Without Alzheimer Disease
  233. Antipsychotic Use and Risk of Hospitalization or Death Due to Pneumonia in Persons With and Those Without Alzheimer Disease
  234. Comparison of predictors of hip fracture and mortality after hip fracture in community-dwellers with and without Alzheimer’s disease – exposure-matched cohort study
  235. Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer’s disease
  236. A Comparison of Sex Differences in Psychotropic Medication Use in Older People with Alzheimer’s Disease in the US and Finland
  237. Differences in analgesic use in community‐dwelling persons with and without Alzheimer's disease
  238. Risk Factors for Initiation of Potentially Inappropriate Medications in Community-Dwelling Older Adults with and without Alzheimer’s Disease
  239. Long-term use of opioids for nonmalignant pain among community-dwelling persons with and without Alzheimer disease in Finland: a nationwide register-based study
  240. Real‐world effectiveness of antipsychotics
  241. Add-on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first-generation antipsychotics
  242. Agreement between PRE2DUP register data modeling method and comprehensive drug use interview among older persons
  243. The effects of a HTR2B stop codon and testosterone on energy metabolism and beta cell function among antisocial Finnish males
  244. Fire-setting performed in adolescence or early adulthood predicts schizophrenia: a register-based follow-up study of pre-trial offenders
  245. Drug use in persons with and without Alzheimer's disease aged 90 years or more
  246. Genome-wide association study of antisocial personality disorder
  247. Influence of a HTR2B Stop Codon on Glucagon Homeostasis and Glucose Excursion in Non-Diabetic Men
  248. Cohort profile: the Finnish Medication and Alzheimer's disease (MEDALZ) study
  249. Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study
  250. Increased steroid hormone dehydroepiandrosterone and pregnenolone levels in post-mortem brain samples of alcoholics
  251. Incidence and Duration of Cumulative Bisphosphonate Use among Community-Dwelling Persons with or without Alzheimer’s Disease
  252. Nurses' Time Use in Forensic Psychiatry
  253. Month and Season of Birth as a Risk Factor for Alzheimer’s Disease: A Nationwide Nested Case-control Study
  254. Incidence of antidepressant use in community‐dwelling persons with and without Alzheimer's disease: 13‐year follow‐up
  255. Conduct disorder in females is associated with reduced corpus callosum structural integrity independent of comorbid disorders and exposure to maltreatment
  256. Impulsive alcohol-related risk-behavior and emotional dysregulation among individuals with a serotonin 2B receptor stop codon
  257. Hospital care and drug costs from five years before until two years after the diagnosis of Alzheimer’s disease in a Finnish nationwide cohort
  258. Incidence of antipsychotic use in relation to diagnosis of Alzheimer's disease among community-dwelling persons
  259. Long-term use of benzodiazepines: Definitions, prevalence and usage patterns – a systematic review of register-based studies
  260. The Incidence of Benzodiazepine and Related Drug Use in Persons with and without Alzheimer’s Disease
  261. Prevalence of Drug Combinations Increasing Bleeding Risk Among Warfarin Users With and Without Alzheimer’s Disease
  262. Long-term use of antipsychotics among community-dwelling persons with Alzheimer׳s disease: A nationwide register-based study
  263. Baseline symptom severity predicts serotonin transporter change during psychotherapy in patients with major depression
  264. Lithium is associated with decrease in all-cause and suicide mortality in high-risk bipolar patients: A nationwide registry-based prospective cohort study
  265. Hospital-treated suicide attempts among Finnish fire setters: a follow-up study
  266. Opioid abuse and hospitalization rates in patients with schizophrenia
  267. A Pilot Study of Group Administered Metacognitive Training (MCT) for Schizophrenia Patients in a High-Security Forensic Setting: Subjective Training Success and Health-Related Quality of Life
  268. Decreased [³H]naloxone Binding in the Dentate Gyrus of Cloninger Type 1 Anxiety-Prone Alcoholics: A Postmortem Whole-Hemisphere Autoradiography Study
  269. Long-term use of benzodiazepines and related drugs among community-dwelling individuals with and without Alzheimer’s disease
  270. Factors Associated with Hospitalization for Blood-Borne Viral Infections Among Treatment-Seeking Illicit Drug Users
  271. Hospitalization in a Cohort Seeking Treatment for Illicit Drug Use in Finland
  272. Psychotropic drugs and homicide: A prospective cohort study from Finland
  273. Potential Years of Life Lost Due to Premature Mortality Among Treatment-Seeking Illicit Drug Users in Finland
  274. From prescription drug purchases to drug use periods – a second generation method (PRE2DUP)
  275. Psychopathic traits among a consecutive sample of Finnish pretrial fire-setting offenders
  276. [3H]Ifenprodil binding in post-mortem brains of Cloninger type 1 and 2 alcoholics: A whole-hemisphere autoradiography study
  277. Characteristics of drug-abusing females with and without children seeking treatment in Helsinki, Finland
  278. Basal insulin secretion, PCL-R and recidivism among impulsive violent alcoholic offenders
  279. Mortality of firesetters: A follow-up study of Finnish male firesetters who underwent a pretrial forensic examination in 1973–1998
  280. Predictors for initiation of pharmacological prophylaxis in patients with newly diagnosed bipolar disorder—A nationwide cohort study
  281. Concomitant Use of Acetylcholine Esterase Inhibitors and Urinary Antispasmodics Among Finnish Community-Dwelling Persons With Alzheimer Disease
  282. Increased Metabotropic Glutamate 2/3 Receptor Binding in the Perigenual Anterior Cingulate Cortex of Cloninger Type 2 Alcoholics: A Whole-Hemisphere Autoradiography Study
  283. Antipsychotic Treatment and Mortality in Schizophrenia
  284. High prevalence of psychotropic drug use among persons with and without Alzheimer׳s disease in Finnish nationwide cohort
  285. Patterns and 14-year trends in mortality among illicit drug users in Finland: The HUUTI study
  286. Genetic background of extreme violent behavior
  287. Lower [3H]Citalopram Binding in Brain Areas Related to Social Cognition in Alcoholics
  288. Corrigendum to “Mortality among clients seeking treatment for buprenorphine abuse in Finland” [Drug Alcohol Depend. 133 (2013) 391–397]
  289. Antipsychotic Doses Among Community-Dwelling Persons With Alzheimer Disease in Finland
  290. Antipsychotic Polypharmacy among a Nationwide Sample of Community-Dwelling Persons with Alzheimer's Disease
  291. The C9ORF72 expansion does not affect the phenotype in Nasu-Hakola disease with the DAP12 mutation
  292. Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland
  293. Association of Socio-Demographic Factors, Sick-Leave and Health Care Patterns with the Risk of Being Granted a Disability Pension among Psychiatric Outpatients with Depression
  294. Mortality among forensic psychiatric patients in Finland
  295. Factors associated with buprenorphine compared to amphetamine abuse among clients seeking treatment in Finland
  296. Metacognitive group training for forensic and dangerous non‐forensic patients with schizophrenia: A randomised controlled feasibility trial
  297. AMPA receptors in post-mortem brains of Cloninger type 1 and 2 alcoholics: A whole-hemisphere autoradiography study
  298. Mortality among clients seeking treatment for buprenorphine abuse in Finland
  299. Patient Safety Culture in Two Finnish State-Run Forensic Psychiatric Hospitals
  300. Previous forensic mental examination is a useful marker indicating effective violence relapse prevention among psychotic patients
  301. Cluster-Randomized Controlled Trial of Reducing Seclusion and Restraint in Secured Care of Men With Schizophrenia
  302. Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer’s disease research – the Medication use among persons with Alzheimer’s disease (MEDALZ-2005) study
  303. Endogenous cannabinoids in amygdala and hippocampus in post-mortem brains of Cloninger type 1 and 2 alcoholics
  304. Cavum septum pellucidum and psychopathy
  305. Exome sequence analysis of Finnish patients with clozapine-induced agranulocytosis
  306. mGluR1/5 receptor densities in the brains of alcoholic subjects: A whole-hemisphere autoradiography study
  307. Violent behaviour in a forensic psychiatric hospital in Finland: an analysis of violence incident reports
  308. Coexisting social conditions and health problems among clients seeking treatment for illicit drug use in Finland: The HUUTI study
  309. Clozapine resistance—Augmentation strategies
  310. Atypical nucleus accumbens morphology in psychopathy: Another limbic piece in the puzzle
  311. Decreased GABAA benzodiazepine binding site densities in postmortem brains of Cloninger type 1 and 2 alcoholics
  312. Extended‐release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double‐blind, placebo‐controlled trial
  313. Word List Learning in Patients with Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy
  314. Influence of Serotonin Transporter Gene Polymorphism (5-HTTLPR Polymorphism) on the Relation between Brain 5-HT Transporter Binding and Heart Rate Corrected Cardiac Repolarization Interval
  315. Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia – A path model investigation
  316. Using the HCR-20 to Predict Aggressive Behavior among Men with Schizophrenia Living in the Community: Accuracy of Prediction, General and Forensic Settings, and Dynamic Risk Factors
  317. Twelve-year trend in treatment seeking for buprenorphine abuse in Finland
  318. Relationships between pharmacotherapy-induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first-generation antipsychotics combination trial
  319. Ketamine in treatment-resistant major depression
  320. Methylphenidate in the treatment of amphetamine dependence: a double-blind randomised, placebo-controlled trial
  321. Naltrexone depot implant in the treatment of co-morbid amphetamine and opioid dependence
  322. Sociodemographic Characteristics and Drug Abuse Patterns of Treatment-Seeking Illicit Drug Abusers in Finland, 1997–2008: The Huuti Study
  323. Description of long-term polypharmacy among schizophrenia outpatients
  324. Outcome of patients after market withdrawal of thioridazine: A retrospective analysis in a nationwide cohort
  325. Rorschach assessment of personality functioning in patients with polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy
  326. Exome Sequencing Followed by Large-Scale Genotyping Suggests a Limited Role for Moderately Rare Risk Factors of Strong Effect in Schizophrenia
  327. Whole-hemisphere autoradiography of 5-HT1B receptor densities in postmortem alcoholic brains
  328. Polypharmacy With Antipsychotics, Antidepressants, or Benzodiazepines and Mortality in Schizophrenia
  329. Naltrexone Implant for the Treatment of Polydrug Dependence: A Randomized Controlled Trial
  330. Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia
  331. Reply to Drs. Nauta and van Domburg
  332. Examining the effectiveness of antipsychotic medication in first-episode psychosis
  333. Antipsychotic polypharmacy in clozapine resistant schizophrenia: a randomized controlled trial of tapering antipsychotic co-treatment
  334. The Substance Use among Forensic Psychiatric Patients
  335. The net effect of smoking on healthcare and welfare costs. A cohort study
  336. Toward Molecular Psychotherapy of Depression?
  337. The Patient–Therapist Interaction and the Recognition of Affects during the Process of Psychodynamic Psychotherapy for Depression
  338. Statin usage and all‐cause and disease‐specific mortality in a nationwide study
  339. Erratum: Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia
  340. The place of observational studies in assessing the effectiveness of depot antipsychotics
  341. Cortex and amygdala morphology in psychopathy
  342. A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia
  343. More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia
  344. Add‐on mirtazapine improves depressive symptoms in schizophrenia: a double‐blind randomized placebo‐controlled study with an open‐label extension phase
  345. Interrelationship between core interventions and core competencies of forensic psychiatric nursing in Finland
  346. Psychopathy, PCL-R, and MAOA genotype as predictors of violent reconvictions
  347. Psychopathic brain -- an unknown challenge for treatment
  348. Gender differences in brain serotonin transporter availability in panic disorder
  349. Group psychoeducation for long‐term offender patients with schizophrenia: An exploratory randomised controlled trial
  350. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial
  351. Serotonin‐transporter‐linked promoter region polymorphism and serotonin transporter binding in drug‐naïve patients with major depression
  352. Extrapyramidal side-effects and dopamine D2/3receptor binding in substantia nigra
  353. MAOA Alters the Effects of Heavy Drinking and Childhood Physical Abuse on Risk for Severe Impulsive Acts of Violence Among Alcoholic Violent Offenders
  354. Endogenous cannabinoids in post-mortem brains of Cloninger type 1 and 2 alcoholics
  355. EFFECTS OF ADD-ON MIRTAZAPINE ON NEUROCOGNITION IN SCHIZOPHRENIA: AN OPEN LABEL EXTENSION PHASE OF A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY, AND BOTH PHASES
  356. The Intergenerational Cycle of Criminality—Association with Psychopathy*
  357. Seasonal variation of seclusion incidents from violent and suicidal acts in forensic psychiatric patients
  358. Dopamine transporter binding in females with panic disorder may vary with clinical status
  359. Predicting forensic admission among the mentally ill in a multinational setting: A Bayesian modelling approach
  360. Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study
  361. Mortality in patients with schizophrenia – Author's reply
  362. Incidence of cancer and antidepressant medication: Record linkage study
  363. Incidence of cancer and statin usage—Record linkage study
  364. Cardiac repolarization and striatal dopamine transporter function are interrelated
  365. Abnormal hippocampal shape in offenders with psychopathy
  366. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)
  367. Dopamine D2/3receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine
  368. Abnormal Cortical Morphology in Offenders with Psychopathy
  369. Low non-oxidative glucose metabolism and violent offending: An 8-year prospective follow-up study
  370. Recidivistic offending and mortality in alcoholic violent offenders: A prospective follow-up study
  371. Altered hemispheric balance of temporal cortex dopamine D2/3 receptor binding in major depressive disorder
  372. Premorbid personality factors in schizophrenia and bipolar disorder: Results from a large cohort study of male conscripts.
  373. The efficacy of lamotrigine in clozapine-resistant schizophrenia: A systematic review and meta-analysis
  374. Antidepressant use and mortality in Finland: a register-linkage study from a nationwide cohort
  375. Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: A double-blind, randomized, placebo-controlled trial
  376. Effects of MAOA‐Genotype, Alcohol Consumption, and Aging on Violent Behavior
  377. 5-HT1A Receptors in the Frontal Cortical Brain Areas in Cloninger Type 1 and 2 Alcoholics Measured by Whole-Hemisphere Autoradiography
  378. Pharmacotherapy of Methamphetamine Addiction: An Update
  379. Brain anatomy of persistent violent offenders: More rather than less
  380. Midbrain serotonin and striatum dopamine transporter binding in double depression: A one-year follow-up study
  381. Association of serotonin transporter promoter regulatory region polymorphism and cerebral activity to visual presentation of food
  382. Predicting Forensic Admission among the Mentally Ill: A Bayesian Approach
  383. Temporal cortex dopamine D2/3 receptor binding in major depression
  384. Striatal dopaminergic terminals in type 1 and type 2 alcoholics measured with [3H]dihydrotetrabenazine and human whole hemisphere autoradiography
  385. Autoradiographic characterization of α2C‐adrenoceptors in the human striatum
  386. Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia
  387. Characterization of metabolic syndrome among forensic psychiatric inpatients
  388. Antidepressant use and mortality in Finland: A register-linkage study from a nationwide cohort
  389. Cortical dopamine D1 receptors in type 1 and type 2 alcoholics measured with human whole hemisphere autoradiography
  390. Changes in midbrain serotonin transporter availability in atypically depressed subjects after oneyear of psychotherapy
  391. Correlation between the SERT binding densities in hypothalamus and amygdala in cloninger type 1 and 2 alcoholics
  392. Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents
  393. Body size and violent offending among males in the Northern Finland 1966 birth cohort
  394. Amygdala serotonin transporters in alcoholics measured by whole hemisphere autoradiography
  395. A Comparison of General Adult and Forensic Patients with Schizophrenia Living in the Community
  396. Energy substrate metabolism among habitually violent alcoholic offenders having antisocial personality disorder
  397. Real-world effectiveness of pharmacological treatments in schizophrenia
  398. Violent persons with schizophrenia and comorbid disorders: A functional magnetic resonance imaging study
  399. Reduced midbrain serotonin transporter availability in drug-naïve patients with depression measured by SERT-specific [123I] nor-β-CIT SPECT imaging
  400. A Multisite Study of Community Treatment Programs for Mentally Ill Offenders With Major Mental Disorders
  401. Functional COMT Val158Met Polymorphism, Risk of Acute Coronary Events and Serum Homocysteine: The Kuopio Ischaemic Heart Disease Risk Factor Study
  402. Transmission of violent offending and crime across three generations
  403. A Comparison of Aripiprazole, Methylphenidate, and Placebo for Amphetamine Dependence
  404. A Comparison of Aripiprazole, Methylphenidate, and Placebo for Amphetamine Dependence
  405. Antidepressants and the Risk of Suicide, Attempted Suicide, and Overall Mortality in a Nationwide Cohort
  406. Visualization of the cortical dopamine transporter in type 1 and 2 alcoholics with human whole hemisphere autoradiography
  407. Nucleus accumbens serotonin transporters in alcoholics measured by whole-hemisphere autoradiography
  408. PMH23 PREDICTING VIOLENT OFFENDING AMONG MENTALLY ILL IN A MULTINATIONAL SETTING–NAIVE BAYESIAN FUSION AND MODEL MERGING WITH P-COURSE
  409. Midbrain binding of [123I]nor-β-CIT in atypical depression
  410. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study
  411. Midbrain dopamine D2/3 receptor binding in schizophrenia
  412. Glutamatergic drugs for schizophrenia
  413. Fatal Agranulocytosis 4 Years After Discontinuation of Clozapine
  414. P.2.c.016 Antidepressant use and the risk of suicide, attempted suicide and overall mortality in a nation-wide cohort
  415. Lower serotonin transporter binding in caudate in alcoholics
  416. Seasonal variations in [3H]citalopram platelet binding between healthy controls and violent offenders in Finland
  417. The consequences of Conduct Disorder for males who develop schizophrenia: Associations with criminality, aggressive behavior, substance use, and psychiatric services
  418. Premorbid Intellectual Functioning in Bipolar Disorder and Schizophrenia: Results From a Cohort Study of Male Conscripts
  419. Topiramate Add-On in Treatment-Resistant Schizophrenia
  420. Subcritical water as eluent for chromatographic separation of carbohydrates using cation-exchange resins
  421. Visualisation of the cortical dopamine D3 receptors in alcoholics and controls with human whole-hemisphere autoradiography
  422. Effects of Venlafaxine Treatment on Clozapine Plasma Levels in Schizophrenic Patients
  423. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis
  424. Striatal dopamine D1 receptors in type 1 and 2 alcoholics measured with human whole hemisphere autoradiography
  425. An Outcome of Psychodynamic Psychotherapy: A Case Study of the Change in Serotonin Transporter Binding and the Activation of the Dream Screen
  426. Dopamine and alcoholism: neurobiological basis of ethanol abuse
  427. Reduced brain serotonin transporter binding in patients with panic disorder
  428. A controlled study of tryptophan and cortisol in violent offenders
  429. SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder
  430. Cortical dopamine D2receptors in type 1 and 2 alcoholics measured with human whole hemisphere autoradiography
  431. Elevated midbrain serotonin transporter availability in mixed mania: a case report
  432. Distribution of 5-HT7 receptors in the human brain: a preliminary autoradiographic study using []SB-269970
  433. THE MEDIAL TEMPORAL LOBE IN ALCOHOLISM AND PSYCHOPATHOLOGY: EVALUATION BY VOLUMETRIC MRI.
  434. MRI volumetry of the vermis and the cerebellar hemispheres in men with schizophrenia
  435. 123I-?-CIT binding and recovery from depression
  436. Brain serotonin 1A receptor binding in bulimia nervosa
  437. Characteristics and circumstances of homicidal acts committed by offenders with schizophrenia
  438. Comorbid Personality Disorders and Substance Use Disorders of Mentally Ill Homicide Offenders: A Structured Clinical Study on Dual and Triple Diagnoses
  439. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial
  440. The amygdala and schizophrenia: a volumetric magnetic resonance imaging study in first-episode, neuroleptic-naive patients
  441. Treatment improves serotonin transporter binding and reduces binge eating
  442. P.3.011 Reduced brain serotonin transporter binding in patients with panic disorder
  443. Dopamine D2 receptors and transporters in type 1 and 2 alcoholics measured with human whole hemisphere autoradiography
  444. Total plasma l‐tryptophan, free l‐tryptophan and competing amino acid levels in a homicidal male adolescent with conduct disorder
  445. Dopamine receptors and transporters in the brain reward circuits of type 1 and 2 alcoholics measured with human whole hemisphere autoradiography☆
  446. Ethanol consumption and DRD2 gene TaqI a polymorphism among socially drinking males
  447. Different effect of age on dopamine transporters in the dorsal and ventral striatum of controls and alcoholics
  448. Alcoholics show altered histaminergic neurotransmission in several cortical areas - Preliminary report
  449. Extrastriatal dopamine D2/3 receptor density and distribution in drug-naive schizophrenic patients
  450. Co-eluent effect in partition chromatography. Rhamnose–xylose separation with strong and weak cation-exchangers in aqueous ethanol
  451. Seasonal variation in specific methods of suicide: a national register study of 20 234 Finnish people
  452. Glutamatergic drugs for schizophrenia
  453. Is occupation relevant in suicide?
  454. Prefrontal volumes in habitually violent subjects with antisocial personality disorder and type 2 alcoholism
  455. Use of Statistical Techniques in Studies of Suicide Seasonality, 1970 to 1997
  456. A volumetric MRI study of the entorhinal cortex in first episode neuroleptic-naive schizophrenia
  457. The quantitative risk of violent crime and criminal offending: a case‐control study among the offspring of recidivistic Finnish homicide offenders
  458. Effect of alcohol abuse on human brain histamine and tele-methylhistamine
  459. Serotonin Transporter Distribution and Density in the Cerebral Cortex of Alcoholic and Nonalcoholic Comparison Subjects: A Whole-Hemisphere Autoradiography Study
  460. Analysis of monoamine oxidase A (MAOA) promoter polymorphism in Finnish male alcoholics
  461. Total serum cholesterol level, violent criminal offences, suicidal behavior, mortality and the appearance of conduct disorder in Finnish male criminal offenders with antisocial personality disorder
  462. Seclusion treatment measures and serum cholesterol levels among Finnish male forensic psychiatric patients
  463. Serum lipid levels and violence among Finnish male forensic psychiatric patients
  464. Impaired Temporal Lobe Processing of Preattentive Auditory Discrimination in Schizophrenia
  465. Dopamine Transporter Density and Novelty Seeking Among Alcoholics
  466. Mortality of antisocial male criminals
  467. Free L -tryptophan plasma levels in antisocial violent offenders
  468. Recidivism Among Serious Violent Crime Offenders in Finland
  469. SPECT and neuropsychological performance in severe depression treated with ECT
  470. Measurement of the Striatal Dopamine Transporter Density and Heterogeneity in Type 1 Alcoholics Using Human Whole Hemisphere Autoradiography
  471. Altered frontal lobe function suggested by source analysis of event-related potentials in impulsive violent alcoholics
  472. Dopamine Transporter in vitro Binding and in vivo Imaging in the Brain
  473. Dopamine Transporter in vitro Binding and in vivo Imaging in the Brain
  474. Reduced serotonin transporter binding in binge eating women
  475. Effects of ageing on serotonin transporters in healthy females
  476. A morphometric MRI study of the hippocampus in first-episode, neuroleptic-naı̈ve schizophrenia
  477. The A1 allele of the D2 dopamine receptor gene is associated with high dopamine transporter density in detoxified alcoholics
  478. Dopamine D2/D3-receptor and transporter densities in nucleus accumbens and amygdala of type 1 and 2 alcoholics
  479. Cluster C personality disorder has no independent effect on striatal dopamine transporter densities in major depression
  480. Mortality of antisocial male criminals
  481. Psychopathy and the posterior hippocampus
  482. Characterization of γ-aminobutyrate type A receptors with atypical coupling between agonist and convulsant binding sites in discrete brain regions
  483. In vivo voltammetry with removable carbon fibre electrodes in freely-moving mice: dopamine release during intracranial self-stimulation
  484. Recidivistic Violent Behavior and Axis I and Axis II Disorders
  485. Patterns of dopamine overflow in mouse nucleus accumbens during intracranial self-stimulation
  486. S19.03 Spet studies on outcome of treatment by psychosocial interventions in depression and hysterical paresthesia
  487. Specific binding and laterality of human extrastriatal dopamine D2/D3 receptors in late onset type 1 alcoholic patients
  488. Forensic Psychiatric Organization in Finland
  489. Suicidal behavior in patients with schizophrenia is related to COMT polymorphism
  490. Ethanol modulates evoked dopamine release in mouse nucleus accumbens: dependence on social stress and dose
  491. Regional cerebral blood flow during exposure to food in obese binge eating women
  492. CYP2A6 genotype and smoking
  493. A volumetric MRI study of the hippocampus in type 1 and 2 alcoholism
  494. Metabolism of [ 123 I]epidepride may affect brain dopamine D 2 receptor imaging with single-photon emission tomography
  495. Association Between the Functional Polymorphism of Catechol‐O‐Methyltransferase Gene and Alcohol Consumption Among Social Drinkers
  496. Association Between the Functional Polymorphism of Catechol-O-Methyltransferase Gene and Alcohol Consumption Among Social Drinkers
  497. Pharmacological Intervention for Preventing Violence Among the Mentally Ill with Secondary Alcohol-And Drug-Use Disorders
  498. Lack of association between the functional variant of the catechol-o-methyltransferase (COMT) gene and early-onset alcoholism associated with severe antisocial behavior
  499. Reversed Hemispheric Asymmetry of Auditory N100m in Schizophrenics
  500. Dopamine-transporter density in nucleus accumbens of type-1 alcoholics
  501. Quantitative MRI of the hippocampus and amygdala in severe depression
  502. Dopamine transporter and D 2 -receptor density in late-onset alcoholism
  503. Erratum to “Mortality among habitually violent offenders”
  504. Iodine-123 labelled PE2I for dopamine transporter imaging: influence of age in healthy subjects
  505. Transient Syncope and ECG Changes Associated With the Concurrent Administration of Clozapine and Diazepam
  506. Outcome of different types of long-term antidepressant treatments: a 3-year follow-up study of 14 182 patients
  507. Pindolol and Major Affective Disorders
  508. Association between low activity serotonin transporter promoter genotype and early onset alcoholism with habitual impulsive violent behavior
  509. Striatal dopamine transporter density in major depression
  510. Dopamine transporter availability and depressive symptoms during alcohol withdrawal
  511. Maternal Smoking During Pregnancy and Risk of Criminal Behavior Among Adult Male Offspring in the Northern Finland 1966 Birth Cohort
  512. Association between the functional variant of the catechol-O-methyltransferase (COMT) gene and type 1 alcoholism
  513. Serum testosterone levels, mental disorders and criminal behaviour
  514. Reply
  515. Mortality among habitually violent offenders
  516. Is a Large Body Size During Childhood a Risk Factor for Later Aggression?
  517. Comparison of Iodine-123 Labelled Nor-β-CIT and β-CIT as Potential Radioligands for Serotonin Transporter Imaging
  518. Schizophrenia and seasonality of admissions: the Northern Finland 1966 birth cohort study
  519. Altered Parallel Auditory Processing in Schizophrenia Patients
  520. Increasing homicide rate in Finland accompanied by decreasing seasonality over the period 1957–95
  521. Chronic pindolol treatment and major affective disorders
  522. Abnormal structure of human striatal dopamine re-uptake sites in habitually violent alcoholic offenders: a fractal analysis
  523. 83 Altered frontal lobe function suggested by erp generator analysis in impulsive violent alcoholics
  524. Fentanyl decreases ?-CIT binding to the dopamine transporter
  525. Imaging the structure of the striatum: a fractal approach to SPECT image interpretation
  526. Seasonal variation in suicide occurrence in Finland
  527. Secular trends in the rates and seasonality of violent and nonviolent suicide occurrences in Finland during 1980–95
  528. Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging
  529. Resersal of cerebral asymmetry in schizophrenia measured with magnetoencephalography
  530. The metabolism of iodine-123 labelled 3-(5-cyclopropyl-1,2,4-oxadiazo-3-yl)-7-iodo-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine (NNC 13-8241) measured in human plasma is only minor
  531. Striatal presynaptic dopamine function in type 1 alcoholics measured with positron emission tomography
  532. The incidence and onset-age of hospitalized bipolar affective disorder in Finland
  533. Schizophrenia, alcohol abuse and violent behaviour
  534. Change in monoamine transporter density related to clinical recovery: A case-control study
  535. Fractal analysis – a new approach in brain receptor imaging
  536. Juvenile mortality, mental disturbances and criminality: a prospective study of the Northern Finland 1966 birth cohort
  537. Parental age gap and child sex ratio—Fact or fiction?
  538. Schizophrenia, Alcohol Abuse, and Violent Behavior: A 26-Year Followup Study of an Unselected Birth Cohort
  539. Iodine-123 labeled nor-?-CIT as a potential tracer for serotonin transporter imaging in the human brain with single-photon emission tomography
  540. Seasonal Variation in the Occurrence of Homicide in Finland
  541. Single-photon emission tomography imaging of monoamine transporters in impulsive violent behaviour
  542. Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis
  543. Fractal analysis of striatal dopamine re-uptake sites
  544. Fractal analysis of striatal dopamine re-uptake sites
  545. Seasonal variation of homicide occurrence in Finland
  546. Specific major mental disorders and criminality: a 26-year prospective study of the 1966 northern Finland birth cohort
  547. Striatal and extrastriatal imaging of dopamine D 2 receptors in the living human brain with [ 123 I]epidepride single-photon emission tomography
  548. Striatal and extrastriatal imaging of dopamine D2 receptors in the living human brain with [123I]epidepride single-photon emission tomography
  549. Dopamine reuptake site densities in patients with social phobia
  550. Schizophrenia, alcohol abuse and violent behaviour
  551. Psychiatric disorders and violent behavior
  552. The predictors of schizophrenia in the 1966 Northern Finland birth cobort study
  553. Impaired adaptation to external input in impulsive violent alcoholics
  554. Characterization of C-11 or I-123 Labelled β-CIT‐FP and β-CIT‐FE Metabolism Measured in Monkey and Human Plasma. Identification of Two Labelled Metabolites with HPLC
  555. Characterization of C-11 or I-123 Labelled ?-CIT-FP and ?-CIT-FE Metabolism Measured in Monkey and Human Plasma. Identification of Two Labelled Metabolites with HPLC
  556. Forensic psychotherapy
  557. Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography
  558. Initial human studies with single-photon emission tomography using iodine-123 labelled 3-(5-cyclopropyl-1,2,4-oxadiazo-3-yl)-7-iodo-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]-benzodiazepine (NNC 13-8241)
  559. Mental Disorders and Homicidal Behavior in Finland
  560. Risk of homicidal behavior among discharged forensic psychiatric patients
  561. Factors associated with homicide recidivism in a 13-year sample of homicide offenders in Finland
  562. Low incidence of mania in northern Finland
  563. Schizophrenia and Homicidal Behavior
  564. Citalopram in the Treatment of Alcoholism: a Double-blind Placebo-controlled Study
  565. Quantitative Risk Assessment of Homicidal Behaviour
  566. Homicidal behaviour and mental disorders
  567. The metabolite pattern of [123I]β-CIT determined with a gradient HPLC method
  568. Drs. Tiihonen and Kuikka Reply
  569. Altered striatal dopamine re-uptake site densities in habitually violent and non-violent alcoholics
  570. Iodine-123 labelledN-(2-fluoroethyl)-2?-carbomethoxy-3?-(4-iodophenyl)nortropane for dopamine transporter imaging in the living human brain
  571. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia
  572. Imaging of serotonin and dopamine transporters in the living human brain
  573. Lipophilic metabolite of [123I]β‐CIT in human plasma may obstruct quantitation of the dopamine transporter
  574. Risk of homicidal behaviour among persons convicted of homicide
  575. Altered cerebral blood flow during hysterical paresthesia
  576. Carbamazepine-induced Changes in Plasma Levels of Neuroleptics
  577. Increase in cerebral blood flow of right prefrontal cortex in man during orgasm
  578. Eltoprazine for aggression in schizophrenia and mental retardation
  579. Long-Term Effects of Bilateral Frontal Lobe Lesions from Neuropsychiatric and Neuroradiological Aspects
  580. Magnetoencephalographic localization of epileptic cortex—impact on surgical treatment
  581. Fast decrement with stimulus repetition in ERPs generated by neuronal systems involving somatosensory SI and SII cortices: Electric and magnetic evoked response recordings in humans
  582. Neuromagnetic mismatch fields to single and paired tones
  583. Eosinophilia associated with clozapine
  584. Magnetoencephalographic 10-Hz rhythm from the human auditory cortex
  585. Reply
  586. Localization of epileptic foci using a large‐area magnetometer and functional brain anatomy
  587. Separate finger representations at the human second somatosensory cortex
  588. Early deflections of cerebral magnetic responses to median nerve stimulation
  589. Evoked responses of human auditory cortex may be enhanced by preceding stimuli
  590. Multichannel detection of magnetic compound action fields of median and ulnar nerves
  591. Paired Tone Presentation Enhances Responses of Human Auditory Cortex to Rare Frequency Changes
  592. Magnetic mu rhythm in man
  593. Evoked and Spontaneous Magnetic Activity of the Human Somatosensory Cortex
  594. Molecular characterization of a Y;15 translocation segregating in a family